Faruqi & Faruqi Investigates Securities Claims Against Avantor Amid Class Action Deadline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: PRnewswire
- Legal Investigation Initiated: Faruq & Faruq LLP is investigating potential securities claims against Avantor, concerning investor losses from March 5, 2024, to October 28, 2025, indicating the company may face legal risks that could impact its market reputation.
- Class Action Reminder: Investors are reminded to apply for lead plaintiff status by December 29, 2025, suggesting that the case may attract significant investor participation, thereby increasing the legal pressure on the company.
- Investor Rights Protection: Faruq & Faruq encourages affected investors to contact them directly, highlighting the importance of protecting investor rights, which may lead to potential liability for the company in legal terms.
- Market Reaction Anticipation: As the legal investigation progresses, Avantor's stock price may experience negative impacts, potentially diminishing investor confidence and affecting the company's long-term financial performance and market positioning.
AVTR
$11.195+Infinity%1D
Analyst Views on AVTR
Wall Street analysts forecast AVTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVTR is 13.86 USD with a low forecast of 12.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 11.240
Low
12.00
Averages
13.86
High
17.00
Current: 11.240
Low
12.00
Averages
13.86
High
17.00
About AVTR
Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company’s segments include Laboratory Solutions and Bioscience Production. Within its segments, it sells materials and consumables, equipment and instrumentation and services and specialty procurement to customers in the biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
